NS1209 and Lidocaine in Patients With Peripheral Neuropathic Pain

Danish Pain Research Center

Status and phase

Completed

Phase 2

Conditions

Pain

Treatments

Drug: Lidocaine

Drug: NS1209

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00258622

NS1209-008

Details and patient eligibility

About

Purpose: To evaluate the efficacy, tolerability and safety of NS1209 compared to lidocaine and placebo in patients with peripheral chronic neuropathic pain.

Enrollment

18 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age >18 years
Neuropathic pain and allodynia after a peripheral nerve injury (VAS >= 4)

Exclusion criteria

Patients who cannot cooperate and do no understand Danish
Fertile women
Clinically significant abnormality or disease
Drug and alcohol abuse
Clinically abnormal ECG
Hypersensitivity to any of the treatments
Patients in treatment with cimetedin, antidepressants, antipsychotics, antiepileptics except gabapentin, anticoagulants, Na channel blockers and beta blockers
Patients who have previously been treated in a NS1209 study
Patients treated with an investigational drug